Cipan

What Cipan does

Cipan is a Portuguese pharmaceutical manufacturer founded in 1960, headquartered in Castanheira do Ribatejo, Portugal. The company specializes in the research, development, and production of active pharmaceutical ingredients (APIs), with a primary focus on anti-infection agents. Cipan operates a B2B model, producing APIs that supply generic and branded drug formulators globally, leveraging its manufacturing facilities in Portugal under pharmaceutical-grade quality and regulatory standards.

The company is publicly listed on Euronext Lisbon under the ticker CPN (eli:CPN) and maintains a lean operational footprint of 51-100 employees, consistent with a focused specialty API producer rather than a diversified pharmaceutical manufacturer. Cipan's product strategy centers on a narrow therapeutic category — anti-infectives — which positions it as a niche supplier within the broader API market, where regulatory qualifications (GMP, DMFs) and long-standing customer relationships are central to competitive positioning.

Cipan's revenue mechanics are not disclosed in available sources, and the company's primary web presence (cipan.pt) returned a loading/verification page during data collection, limiting insight into product portfolio depth, customer mix, pricing structure, or recent commercial developments. The publicly listed status on Euronext Lisbon implies periodic financial disclosure obligations, though those filings were not captured in the source data provided. As a small-cap, single-site, specialty API manufacturer with six decades of operating history, Cipan's investment profile is shaped by the structural durability of anti-infection API demand alongside concentration risk in a narrow product set and geography.

Name

Cipan

Website

https://cipan.pt

Company type

Private

Founded year

1960

Headcount range

51–100 employees

Short description

Cipan is a Portuguese pharmaceutical company, publicly listed on Euronext Lisbon, that researches, develops, and manufactures active pharmaceutical ingredients (APIs) with a primary focus on anti-infection agents for B2B pharmaceutical customers.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing (Active Pharmaceutical Ingredients)

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

Keywords

• Active pharmaceutical ingredients
• Anti-infection APIs
• Pharmaceutical manufacturing
• API production
• Generic drug ingredients

Headquarters

HQ city

Castanheira Do Ribatejo

HQ country

Portugal

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure

Core offering

Cipan researches, develops, and produces active pharmaceutical ingredients (APIs), with its core focus on anti-infection agents. The company operates as a specialty API manufacturer based in Castanheira do Ribatejo, Portugal, supplying ingredient materials to downstream pharmaceutical formulators and drug producers.

Differentiator

Problem solved

Functional benefit

Products and services

• Anti-infection Active Pharmaceutical Ingredients (APIs)

Ideal customer profiles1 record

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Broad incumbents

• Aurobindo Pharma: Large Indian manufacturer of generic APIs and finished dosages with a leading share of the global anti-infective market. Comparable in product category but operates at far greater scale than Cipan and competes with it on price.
• Dr. Reddy's Laboratories: Indian-headquartered global generic API and finished-form drug producer with strong anti-infective presence. Overlaps with Cipan on generic API supply, especially antibacterials, though it spans many therapeutic areas and dosages.
• Teva API: API division of Teva Pharmaceutical Industries producing generic and specialty APIs including anti-infectives. Comparable as a large-scale commercial API manufacturer competing for the same global generic drug formulators as Cipan.
• Johnson Matthey (Health): UK-listed specialty chemicals and API manufacturer with a Health segment supplying catalyst, chemistry, and API services including anti-infectives. Comparable in supplying regulated European pharmaceutical customers with API/intermediate solutions.
• Lupin Pharmaceuticals: Major Indian generic API and finished-dose manufacturer with substantial anti-infective (including tuberculosis and cephalosporin) franchise. Similar API category exposure but operates at significantly larger global scale.

Direct peers

• Hovione: Portugal-based, privately held developer and manufacturer of active pharmaceutical ingredients and intermediates. Highly comparable to Cipan given shared Portuguese base, API focus, and integrated drug substance capabilities.
• Seqens: France-headquartered integrated API and intermediates manufacturer serving pharmaceutical customers across therapeutic classes including anti-infectives. Comparable in being a European specialty API producer competing against Asian generic supply.
• EuroAPI: European-focused API manufacturer spun out from Sanofi, supplying generic and branded APIs globally including anti-infectives. Directly comparable in API production scope, with larger scale but same European regulatory positioning as Cipan.
• Cambrex: US-headquartered contract developer and manufacturer of small-molecule APIs and intermediates. Comparable in API manufacturing capability and customer base (small/mid pharma formulators), though with a heavier custom/CDMO mix than Cipan.

Emerging players

• Dishman Carbogen Amcis: India-based API and intermediates manufacturer offering anti-infective and complex chemistry APIs. Competes with Cipan for the same European anti-infective formulators from a low-cost base.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cipan